Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells

Abstract : We have previously shown that growth of HT29 human colorectal cancer cells at confluence increased their resistance to the cytotoxic agent cisplatin. This study further explores the mechanisms of this resistance phenotype. DNA platination induced by cisplatin exposure is slightly reduced by confluence. However, at an equivalent DNA platination level, non-confluent cells accumulate in the G2/M phase of the cell cycle, demonstrate aberrant mitotic figures and die by apoptosis, while confluent cells progress slowly through the cell cycle, do not reach mitosis and are more resistant to drug-induced cell death. At a molecular level, cisplatin enhances cyclin B and p34cdc2 levels and histone H1 kinase activity in non-confluent, but not in confluent, cells. Furthermore, when HT29 cells reach confluence, expression of the cyclin-dependent kinase inhibitor p27Kip1 increases and cells accumulate in the G0/G1 phase of the cell cycle. Transfection-mediated over-expression of p27Kip1 in non-confluent HT29 cells decreases the cytotoxic activity of cisplatin as well as its ability to trigger apoptosis. Non-confluent HT29 cells over-expressing p27Kip1 are also more resistant to doxorubicin, etoposide and 5-fluorouracil. Our results suggest that p27Kip1 contributes to the confluence-dependent resistance phenotype.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02345503
Contributor : Beatrice Eymin <>
Submitted on : Monday, November 4, 2019 - 3:22:47 PM
Last modification on : Wednesday, November 6, 2019 - 1:50:39 AM

Identifiers

Citation

Marie-Thérèse Dimanche-Boitrel, Olivier Micheau, Arlette Hammann, Monika Haugg, Béatrice Eymin, et al.. Contribution of the cyclin-dependent kinase inhibitor p27KIP1 to the confluence-dependent resistance of HT29 human colon carcinoma cells. International Journal of Cancer, Wiley, 1998, 77 (5), pp.796-802. ⟨10.1002/(sici)1097-0215(19980831)77:5<796::aid-ijc20>3.0.co;2-z⟩. ⟨inserm-02345503⟩

Share

Metrics

Record views

7